P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL

• Heng Mei,
• Hu Zhou,
• Ming Hou,
• Jing Sun,
• Lei Zhang,
• Jianmin Luo,
• Zhongxing Jiang,
• Xu Ye,
• Yajing Xu,
• Jun Lu,
• Hui Wang,
• Aimin Hui,
• Yongchun Zhou,
• Yu Hu

Affiliations

Heng Mei

1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Hematology, wuhan, China

Hu Zhou

2 Henan Cancer Hospital, Department of Hematology, Zhengzhou, China

Ming Hou

3 Qilu Hospital of Shandong University, Cancer Center, Jinan, China

Jing Sun

4 Nanfang Hospital, Department of Hematology, Guangzhou, China

Lei Zhang

5 Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Jianmin Luo

6 The Second Hospital of Hebei Medical University, Department of Hematology, Shijiazhuang, China

Zhongxing Jiang

7 The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Xu Ye

8 The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Yajing Xu

9 Xiangya Hospital, Central South University, Department of Hematology, Changsha, China

Jun Lu

10 Fosun Pharma, shanghai, China

Hui Wang

10 Fosun Pharma, shanghai, China

Aimin Hui

10 Fosun Pharma, shanghai, China

Yongchun Zhou

11 Wanbang Biopharmaceuticals, xuzhou, China

Yu Hu

1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Hematology, wuhan, China